Concepedia

Roger DeRaad

RD

3

Publications

278

Citations

3

H-Index

2010

Active since

Affiliations

Eli Lilly (United States)(Current)

University of Oklahoma Health Sciences Center

University of Florida

Roger DeRaad is an author at Eli Lilly (United States) specializing in pharmacotherapy, thrombosis, and medicine.

Top concepts

MedicineCardiologyHematologyThrombosisPharmacologyPharmacotherapyCardiovascular DiseaseHealthPublic HealthAnesthesiology

Publications per year

2010–2023

3

Publications

3

Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes

Dominick J. Angiolillo, Jorge F. Saucedo, Roger DeRaad et al. · Journal of the American College of Cardiology · 2010 · 166 citations

Thrombopoiesis, Thrombosis, Cardiovascular Disease +14

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study

Dominick J. Angiolillo, Roger DeRaad, Andrew L. Frelinger et al. · Thrombosis and Haemostasis · 2012 · 24 citations

Thrombosis, Percutaneous Coronary Intervention, Platelet Reactivity Index +15

Rows per page

1–3 of 3